Menu
Recruiting NCT06924359

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

— Observational Alzheimer's Disease (AD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Multimodal Ophthalmic Imaging and plasma biomarker.
Who it may be relevant to
Registry conditions: Alzheimer's Disease (AD). Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Interventions

  • Diagnostic test Multimodal Ophthalmic Imaging and plasma biomarker
    Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.

Primary outcome measures

  • Differences in Multimodal Ophthalmic Imaging parameter values among groups [Time frame: Baseline]
Secondary outcome measures (1)
  • Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Male or female participants aged ≥ 50 years;
  • Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
  • Signed informed consent form

Exclusion criteria

  • Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
  • Inability to cooperate with cognitive assessments;
  • Refusal to undergo blood sampling.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-control

Study locations

China · 1 center
  • Peking University First Hospital — Beijing

Identifiers

NCT: NCT06924359 · AD-BIOPR-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗